The studies show that the concentration of IL-18 in the blood serum of patients with prostate cancer is significantly higher than in healthy patients from the control group (345 ± 94.8 pg/ml vs. 180 ± 54.1 pg/ml, p < 0.05) [52]. Here, IL18 is linked to prostate carcinoma.